Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

When compared with observation, adjuvant crizotinib did not improve disease-free survival or overall survival in ALK-positive NSCLC.

Jacob Sands, MD

August 4th 2025

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Kyle Doherty

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

The median CNS PFS with Dato-DXd was 5.0 months vs 3.0 months with docetaxel in patients with NSCLC who have brain metastases.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Roman Fabbricatore

Zidesamtinib Exhibits Durable Activity in Pretreated ROS1+ Advanced NSCLC

The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Zidesamtinib was well tolerated in patients who received prior ROS1 TKI therapy with advanced NSCLC, and dose discontinuation/reduction rates were low.

Caroline Seymour

Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC

Zidesamtinib was well tolerated in patients who received prior ROS1 TKI therapy with advanced NSCLC, and dose discontinuation/reduction rates were low.

Related Content

Jax DiEugenio

September 9th 2025

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

When compared with observation, adjuvant crizotinib did not improve disease-free survival or overall survival in ALK-positive NSCLC.

Jacob Sands, MD

August 4th 2025

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Kyle Doherty

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

The median CNS PFS with Dato-DXd was 5.0 months vs 3.0 months with docetaxel in patients with NSCLC who have brain metastases.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Roman Fabbricatore

Zidesamtinib Exhibits Durable Activity in Pretreated ROS1+ Advanced NSCLC

The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Caroline Seymour